Could a bidding war for Brazil’s privately held Ache Laboratorios do for Latin America what Abbott Laboratories Inc.’s gargantuan purchase of part of India’s Piramal Enterprises Ltd. did for biopharma M&A in India?
Call it the “Piramal effect,” if you will. Abbott reset expectations among India’s domestic pharma world with its $3.72 billion...